Avigan showed it reduced recovery times for COVID-19 patients with non-severe symptoms, boosting expectations for regulatory approval in Japan.The Phase 3 clinical study of 156 patients in Japan showed that those treated with Avigan improved after 11.9 days, versus 14.7 days for a placebo group.
Results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were statistically significant, the company said in a release.The announcement sent Fujifilm shares up more than 4% in Tokyo to their highest level in four months.Former Japanese Prime Minister Shinzo Abe had touted Avigan's potential as Japan's contribution to a global race for coronavirus treatments, aiming for domestic approval in May.The government called on Fujifilm to.